We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis. Sixty-seven episodes of spontaneous bacterial peritonitis and 60 episodes of bacteremia occurred in, respectively, 46 patients (group 1a) and 52 patients (group 1b) who did not receive norfloxacin, while 23 and 17 episodes occurred in 21 patients (group 2a) and 17 patients (group 2b) during or within 10 days after long-term administration of norfloxacin. Enterobacteriaceae were more prevalent in groups 1a and 1b than in the other two groups (P õ .001 and P õ .01, respectively); conversely, staphylococci were more prevalent in groups 2a and 2b (P õ .001 and P õ .05, respectively). The rate of staphylococcal resistance to methicillin was 53.6% in groups 1a and 1b and 77.3% in groups 2a and 2b. We conclude that long-term norfloxacin administration to cirrhotic patients reduces the risk of gram-negative infections but increases the risk of severe hospital-acquired staphylococcal infections and of high-level resistance to antibiotics.
Bacterial infections are a major cause of morbidity and morPatients and Methods tality among patients with severe cirrhosis [1] . The most frequent infections are spontaneous bacterial peritonitis (SBP), From 1 January 1992 through 31 December 1996, 90 consecurinary tract infections, pneumonia, skin infections, and septiutive episodes of SBP and 77 consecutive episodes of bactercemia [1] . As SBP is the most frequent septic complication (1- emia occurred involving 67 and 69 cirrhotic patients, respecyear probability, 29%), prophylaxis based on selective intestitively. Fifteen patients had simultaneous SBP and bacteremia. nal decontamination with nonabsorbable antibiotics, partially
Patients with clinical and laboratory data suggesting secondary absorbable antibiotics (fluoroquinolones), and systematically peritonitis were excluded. All these patients had a history of absorbed antibiotics (trimethoprim-sulfamethoxazole) has been liver cirrhosis and had been hospitalized elsewhere for at least proposed [2 -6] . Long-term administration of quinolones (nor-2 weeks prior to admission to our liver unit for severe complicafloxacin or ciprofloxacin) prevents recurrences of SBP by retions such as gastrointestinal bleeding, encephalopathy, refracducing the incidence of aerobic gram-negative infections [4, 5, tory ascites, SBP, or other septic complications. The cirrhosis 7]. However, this approach potentially selects highly resistant was alcoholic in 90% of cases. gram-negative pathogens and may lead to the emergence of Patients were classified in four groups. Patients in groups gram-positive pathogens.
1a and 1b did not receive norfloxacin before the diagnosis of We studied the effects of long-term administration of noreither SBP (group 1a; 46 patients and 67 episodes of SBP) or floxacin on the epidemiology of severe infections in hospitalbacteremia (group 1b; 52 patients and 60 episodes of bacterized patients with advanced cirrhosis. We focused on SBP and emia). The patients in these two groups received no other antibacteremia, as they are life-threatening complications that can biotics in the month preceding the onset of SBP or bacteremia. easily be documented by culture of ascitic fluid and blood. We Patients in group 2a (21 patients) had received norfloxacin determined the prevalence of organisms cultured in ascitic fluid (400 mg/d) for more than 1 month before the diagnosis of SBP and blood and the level of resistance to antibiotics. The findings (9 patients) or had stopped receiving norfloxacin within 10 were compared with those regarding patients who had never days before the diagnosis (12 patients). Patients in group 2b undergone selective intestinal decontamination.
(17 patients) had received norfloxacin (400 mg/d) for more than 1 month before the diagnosis of bacteremia (10 patients) or had stopped receiving norfloxacin within 10 days before the NOTE. Data are means { SD, except as otherwise indicated. Group 1a Å patients with SBP not treated with norfloxacin; group 2a Å patients with SBP treated with norfloxacin (n Å 9) and patients from whom norfloxacin was withdrawn within 10 days before the diagnosis of SBP (n Å 12); group 1b Å patients with bacteremia not treated with norfloxacin; group 2b Å patients with bacteremia treated with norfloxacin (n Å 10) and patients from whom norfloxacin was withdrawn within 10 days before the diagnosis of bacteremia (n Å 7). Child classification: group A Å patients with good liver function; group B Å patients with mild liver failure; group C Å patients with severe liver failure.
Norfloxacin was given to patients before admission to our in the polymorphonuclear cell count but with abdominal pain and fever (11 episodes) [8, 9] . This symptomatic form of bactunit, for prevention of recurrence of SBP (40 cases) or as prophylaxis against bacterial infections (in the remaining cases, erascites is considered to be a variant of SBP [10, 11] . The diagnosis of bacteremia was based on a combination of clinical involving poor liver function and/or a low ascitic fluid protein level). The duration of norfloxacin prophylaxis ranged from 1 signs (fever, hypothermia, encephalopathy, and hypotension) and one positive blood culture (17 episodes) or two or more to 6 months. From 1 January 1992 through 31 December 1994, 69 patients received long-term prophylaxis with norfloxacin positive blood cultures (60 episodes). Contaminants in ascitic fluid and blood cultures were excluded. during hospitalization in our unit. Among these 69 patients, 5 had an episode of SBP, 6 had an episode of bacteremia, and Blood and ascitic fluid were collected in blood culture bottles at the bedside, incubated at 37ЊC for 7 days, and examined 4 had episodes of SBP and bacteremia simultaneously. Among our patients receiving long-term norfloxacin prophylaxis, the daily for visual evidence of growth. Bottles were then subcultured after 2 and 7 days on chocolate-enriched agar plates for incidence rates of SBP and bacteremia were 13.0% and 8.7%, respectively. Thereafter, prophylactic norfloxacin was withaerobic and anaerobic growth. The plates were subsequently incubated for 2 days at 37ЊC. Aerobic and facultative aerobic drawn from patients a few days after their admission to our unit.
organisms were identified by their biochemical characteristics. All isolates were tested for antibiotic susceptibility by the semiThe principal characteristics of patients are shown in table 1, and septic complications before referral to our institution solid agar dilution method (ATB; bioMérieux, Marcy l'Etoile, France). are shown in table 2. Five patients in group 1a (11%), 5 in group 2a (23%), 5 in group 1b (10%), and 2 in group 2b (12%) were receiving steroids for alcoholic hepatitis at the time of of staphylococci in our unit decreased from 60% to 45% after we stopped long-term administration of norfloxacin. The rate Organisms isolated in ascitic fluid and blood cultures in the four groups of patients are shown in table 3. Enterobacteriaceae of methicillin resistance among staphylococci isolated from the entire population of inpatients in our hospital increased slightly, family species were the predominant isolates in group 1a (56.8%; mainly Escherichia coli, 38.8%). Gram-positive cocci from 49% in 1992 to 53% in 1996. were predominant in group 1b (56.7%; staphylococci, 36.7%, and E. coli, 28.3%). Gram-positive cocci were highly predomiOutcome and Survival nant in groups 2a and 2b (69.5% and 82%, respectively; Staphylococcus aureus and coagulase-negative staphylococci com-SBP and bacteremia were initially treated with third-generation cephalosporins. Then antibiotherapy was adapted to the bined, 43.5% and 70.6%, respectively). There were significant differences between groups 1a and 2a and between groups 1b susceptibility of isolated bacteria to antibiotics; vancomycin was used in the cases involving methicillin-resistant strains of and 2b regarding the percentages of Enterobacteriaceae isolates (group 1a vs. group 2a: 56.8% vs. 17.2%, P õ .001; group 1b staphylococci. Twenty-six patients in group 1a (57%), 14 in group 2a (67%), 35 in group 1b (67%), and 12 in group 2b vs. group 2b: 38.4% vs. 0, P õ .01) and of staphylococcal isolates (group 1a vs. group 2a: 9% vs. 43.5%, P õ .001; group (71%) died in the liver unit. There was no significant difference in the mortality rates. 1b vs. group 2b: 36.7% vs. 70.6%, P õ .05).
Resistance of Enterobacteriaceae isolates to fluoroquinoDeath occurred after a mean of 34.9 { 58.6 days in group 1a (range, 0 -270 days), 22.7 { 33.4 days in group 2a (range, lones and of staphylococcal isolates to methicillin is shown in table 4. Sixteen percent of Enterobacteriaceae isolates in group 0 -130 days), 11.1 { 13.3 days in group 1b (range, 0 -46 days), and 25.7 { 53.4 days in group 2b (range, 0 -215 days), 1a and 13% in group 1b were resistant. Two of the four Entero-/ 9c4c$$my04 04-10-98 00:08:15 cidal UC: CID negative organisms resistant to quinolones is extremely uncommon in patients with cirrhosis receiving prophylactic norfloxacin; however, only 30% of the cases of SBP were hospitalDiscussion acquired in this study [12] . On the other hand, Novella et al. showed that the overall incidence of infections caused by As in previous studies, organisms of the Enterobacteriaceae norfloxacin-resistant bacteria tended to be higher among pafamily were the main isolates from the patients with SBP who tients receiving long-term norfloxacin prophylaxis than among did not receive norfloxacin prophylaxis [1] . Aerobic grampatients receiving norfloxacin only during hospitalization [13] . positive bacteria were predominant in patients with bacteremia, As mentioned above, the patients in our study were probably regardless of norfloxacin prophylaxis. In this group staphylomore severely ill, as shown by their lower in-hospital survival cocci were as frequent as Enterobacteriaceae. Two factors may rate (35%) despite the use of adapted antibiotherapy; indeed, contribute to this difference. First, sources other than the intestithe expected survival rate is 70% -80% after an episode of nal flora may lead to bacteremia. Second, all the infections in SBP [14, 15] . Moreover, they had hospital-acquired infections, our population were hospital-acquired.
which may involve organisms different from those involved in Norfloxacin has proven effective in secondary prevention of community infections and that may have greater resistance. SBP in patients with cirrhosis. Norfloxacin eliminates aerobic From 13% to 16% of the Enterobacteriaceae isolated from gram-negative bacilli from the intestinal flora but preserves patients who did not receive norfloxacin were fluoroquinoloneother aerobic and anaerobic bacteria [4] . Previous studies have resistant, and staphylococci were found in almost 40% of pashown that norfloxacin prevents recurrence of SBP by reducing tients in this group who had bacteremia (group 1b). Previous the rate of infections caused by Enterobacteriaceae [4, 5]. Our septic complications (found in ú50% of patients) and longresults agree with these previous studies, since in the groups term use of antibiotics probably contributed to this emergence. of patients receiving norfloxacin only 17% of isolated organWe found that long-term norfloxacin administration resulted isms in ascitic fluid were Enterobacteriaceae that were not in a sharp increase in staphylococcal SBP and bacteremia, found in blood cultures.
while the prevalence of Enterobacteriaceae and streptococci, Among our hospitalized patients receiving long-term norrespectively, fell and did not change. Carratala et al. have floxacin prophylaxis, 13.0% had an episode of SBP and 8.7%
shown that norfloxacin prophylaxis in patients with cancer may had an episode of bacteremia. A more advanced disease may result in the emergence of quinolone-resistant E. coli in the account for these higher incidence rates in comparison with fecal flora and quinolone-resistant E. coli bacteremia in neutrothose in previous studies [4, 5] . The effect of widespread norpenic patients [16, 17] . Furthermore, we have previously found floxacin use on the epidemiology of severe infections in cirthat long-term administration of norfloxacin to cirrhotic parhotic patients is poorly known, and the risk of emergence of tients results in the emergence of quinolone-resistant Enteroresistant strains is controversial. Previous studies suggested that this risk is low, as the few SBP recurrences in patients receiving bacteriaceae and staphylococci in the fecal flora [18] .
